Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Absci Corp

Healthcare US ABSI

6.975USD
1.03(17.42%)

Last update at 2026-06-04T18:11:00Z

Day Range

5.927.25
LowHigh

52 Week Range

2.245.23
LowHigh

Fundamentals

  • Previous Close 5.94
  • Market Cap604.43M
  • Volume6074524
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-112.97600M
  • Revenue TTM2.80M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM -77.91800M
  • Diluted EPS TTM-0.84

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -115.11400M -103.03600M -110.46600M -105.36500M -109.85900M
Minority interest - - - - -
Net income -115.18300M -103.10600M -110.56600M -104.90400M -100.96000M
Selling general administrative 35.06M 36.17M 36.26M 40.55M 28.78M
Selling and marketing expenses - - - - -
Gross profit -8.94200M -57.92500M -41.84900M 5.75M 4.78M
Reconciled depreciation 11.74M 13.39M 14.10M 13.04M 6.65M
Ebit -124.71800M -107.48800M -93.68000M -106.75000M -75.23800M
Ebitda -112.97600M -94.09900M -79.68100M -91.35600M -99.77300M
Depreciation and amortization 11.74M 13.39M 14.00M 15.39M -24.53500M
Non operating income net other - - - - -31.18900M
Operating income -124.71800M -108.88800M -115.51500M -106.75000M -75.23800M
Other operating expenses 127.52M 113.42M 121.23M 112.50M 80.02M
Interest expense 0.21M 0.56M 1.01M 0.97M 3.43M
Tax provision 0.07M 0.07M -0.44800M -0.46100M -8.89900M
Interest income - - - - -
Net interest income -0.20900M -0.56500M -1.09300M -0.97200M -3.43200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.07M 0.07M 0.10M -0.46100M -8.89900M
Total revenue 2.80M 4.53M 5.72M 5.75M 4.78M
Total operating expenses 115.78M 50.96M 73.67M 112.50M 80.02M
Cost of revenue 11.74M 62.46M 47.57M - 6.65M
Total other income expense net 9.60M 5.85M 5.05M 1.39M -34.62100M
Discontinued operations - - - - -
Net income from continuing ops -115.18300M -103.10600M -106.49200M -104.90400M -100.96000M
Net income applicable to common shares - - - -104.90400M -103.24400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 216.30M 213.61M 234.48M 321.01M 426.19M
Intangible assets 41.51M 44.88M 48.25M 51.62M 54.99M
Earning assets - - - - -
Other current assets 5.28M 21.41M 4.54M 5.86M 8.57M
Total liab 26.85M 34.48M 58.30M 46.59M 60.09M
Total stockholder equity 189.45M 179.13M 176.18M 274.41M 366.11M
Deferred long term liab - - - - 0.74M
Other current liab 16.59M 19.59M 19.30M 20.48M 17.43M
Common stock 0.01M 0.01M 0.00900M 0.00900M 0.00900M
Capital stock 0.01M 0.01M 0.00900M 0.00900M 0.00900M
Retained earnings -624.78400M -509.60100M -406.49500M -295.92900M -191.02500M
Other liab - - - 0.27M 12.90M
Good will - - 0.00000M 21.34M 21.34M
Other assets - - 0.00000M 3.15M 18.14M
Cash 20.02M 41.21M 88.56M 59.95M 252.57M
Cash and equivalents - - - - -
Total current liabilities 22.77M 28.66M 29.56M 30.27M 33.86M
Current deferred revenue 0.74M 1.12M 3.17M 0.45M 1.35M
Net debt -14.72300M -31.10800M -72.59800M -36.97200M -232.55800M
Short term debt 2.68M 4.42M 5.58M 6.93M 6.69M
Short long term debt 0.87M 2.73M 3.26M 2.95M 2.40M
Short long term debt total 5.30M 10.11M 15.96M 22.98M 20.01M
Other stockholder equity 813.63M 688.73M 582.70M 570.45M 130.94M
Property plant equipment - - - 58.04M 58.65M
Total current assets 149.57M 133.83M 120.58M 186.86M 273.08M
Long term investments - - - - -
Net tangible assets - - - 201.46M 289.78M
Short term investments 124.27M 71.21M 25.30M 104.48M -
Net receivables - 0.00000M 2.19M 1.55M 1.43M
Long term debt - 1.26M 4.66M 7.98M 1.12M
Inventory - - - 15.02M 10.51M
Accounts payable 2.76M 3.53M 1.50M 2.41M 8.38M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.59M -0.00400M -0.03700M -0.12000M -0.01300M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.00900M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -191.02500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.44M 1.76M 1.54M 3.15M 18.14M
Deferred long term asset charges - - - - -
Non current assets total 66.72M 79.78M 113.90M 134.15M 153.12M
Capital lease obligations 4.43M 6.12M 8.04M 12.05M 16.49M
Long term debt total - - - - 1.12M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -50.36500M -41.57700M 32.81M -126.98200M -1.20000M
Change to liabilities - - - -1.44000M 2.15M
Total cashflows from investing activities -50.16000M -41.57700M 81.94M -126.98200M -67.37700M
Net borrowings -3.19600M -4.03100M -5.34500M 4.58M 123.40M
Total cash from financing activities 105.95M 82.53M -4.48300M 5.24M 336.19M
Change to operating activities - - - 0.05M -3.67300M
Net income -115.18300M -103.10600M -110.56600M -104.90400M -100.96000M
Change in cash -37.13600M -31.45300M 12.82M -203.08400M 208.22M
Begin period cash flow 58.21M 89.67M 76.84M 279.93M 71.71M
End period cash flow 21.08M 58.21M 89.67M 76.84M 279.93M
Total cash from operating activities -92.92500M -72.40200M -64.63600M -81.33900M -60.59800M
Issuance of capital stock 105.83M 86.56M 0.79M 0.66M 215.34M
Depreciation 11.74M 13.39M 14.00M 13.04M 6.65M
Other cashflows from investing activities - 0.94M 0.25M 0.65M -29.33000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.00000M 2.24M -0.66600M -0.14800M 0.23M
Sale purchase of stock - - - - 210.40M
Other cashflows from financing activities - - 81.94M 12.03M 129.94M
Change to netincome - - - 12.07M 2.01M
Capital expenditures 1.11M 0.40M 0.86M 16.18M 38.05M
Change receivables - - - - -
Cash flows other operating - - - - 29.55M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - 208.22M
Change in working capital 0.42M -0.36800M 1.52M -1.54000M -3.14600M
Stock based compensation 18.32M 19.45M 11.42M 12.54M 10.61M
Other non cash items -8.22800M -1.76900M 19.05M 0.03M 35.15M
Free cash flow -94.03200M -72.80600M -65.49600M -97.51400M -98.64500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ABSI
Absci Corp		 1.03 17.42% 6.97 - - 215.87 3.19 166.23 -0.3911
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corp

18105 SE Mill Plain Boulevard, Vancouver, WA, United States, 98683

Key Executives

Name Title Year Born
Mr. Sean McClain Founder, CEO, Pres & Director 1991
Dr. Sarah Korman J.D., Ph.D. Chief Legal Officer & Corp. Sec. 1979
Mr. Gregory T. Schiffman CPA, CPA, MBA Chief Financial Officer 1957
Todd Bedrick CPA Sr. VP & Chief Accounting Officer NA
Mr. Jack Gold Chief Marketing Officer NA
Melissa Patterson Ph.D. Chief of Staff NA
Ms. Denise Dettore Chief People Officer NA
Dr. Andreas Busch Ph.D. Chief Innovation Officer 1963
Jonathan Eads M.S. Sr. VP of Informatics NA
Thomas Wrona J.D., Ph.D. Sr. VP of Intellectual Property NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions